Skip to main content
TipRanks
Go Ultimate75% OFF

Peter Barton Hutt Insider Profile

4 Followers

Peter Barton Hutt, Director at Moderna, holds 0.00 shares in Concert Pharma (Ticker: CNCE), holds 0.00 shares in Immunomedics (Ticker: IMMU), holds 3.92K shares in Moderna (Ticker: MRNA).

Peter Barton Hutt's Trading History

CNCE
Concert Pharma
Mar 06, 2023―Uninformative Sell―$0.00
IMMU
Immunomedics
Oct 23, 2020―Uninformative Sell―$0.00
MRNA
Moderna
Nov 22, 2019DirectorUninformative Buy8.00K$876.50K
DCOY
Decoy Therapeutics
Feb 04, 2015DirectorUninformative Buy―$11.38K
MNTA
Momenta Pharma
Sep 15, 2014―Informative Sell41.57K$352.93K
BINDQ
DNIB Unwind, Inc.
―――$0.00
XOMA
XOMA Royalty Corporation
―――$0.00
MCRB
Seres Therapeutics
―Director――

You May Also Like

Peter Barton Hutt insider profile FAQ

What is the percentage of profitable transactions made by Peter Barton Hutt?
The percentage of profitable transactions made by Peter Barton Hutt is 0%.
What is the average return per transaction made by Peter Barton Hutt?
The average return per transaction made by Peter Barton Hutt is -243.30%.
What stocks does Peter Barton Hutt hold?
Peter Barton Hutt holds: MRNA, IMMU, DCOY, MCRB, CNCE, XOMA, BINDQ, MNTA stocks.
What was Peter Barton Hutt's most profitable transaction?
Peter Barton Hutt’s most profitable transaction was an Informative Sell of MNTA stock on September 15, 2014. The return on the trade was -65.50%.
What is Peter Barton Hutt's role in Moderna?
Peter Barton Hutt's role in Moderna is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.